Novo Nordisk Tie-Up, Strong Growth Lift Emcure Pharma Q3 Profit 48% to Rs 231 Cr
Emcure reported a Profit After Tax (PAT) of Rs 156 crore for the October-December period of last fiscal.
Written By : sheeba farhat
Published On 2026-02-05 10:59 GMT | Update On 2026-02-05 10:59 GMT
Advertisement
New Delhi: Emcure Pharmaceuticals on Wednesday posted a 48 per cent year-on-year increase in its consolidated profit after tax at Rs 231 crore for the third quarter ended December 31, 2025, led by robust sales growth in business verticals.
The drug firm reported a Profit After Tax (PAT) of ₹156 crore for the October-December period of last fiscal.
Revenue from operations increased to ₹2,363 crore for the period under review as against ₹1,963 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. Emcure Pharmaceuticals CEO and MD Satish Mehta said Q3 delivered a strong performance, with all its businesses outpacing industry growth.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.